Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus denosumab for metastatic clear cell renal cell carcinoma
ACTRN12618000132246Phase 2Terminated
- Sponsor
- ANZUP Cancer Trials Group
- Start
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC), sponsored by ANZUP Cancer Trials Group. Primary endpoint: Objective tumour response rate. Started Dec 2017; status: terminated.
02
Drugs
pembrolizumabdenosumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ACTRN12618000132246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000132246.